Compounded Tirzepatide Recall in 2026: How to Check Your Vials After the Apothecary Pharma Sterility Alert

Apothecary Pharma LLC, an FDA-registered 503B outsourcing facility, began voluntarily recalling its compounded tirzepatide injection in late September after it could not verify the product was made under sterile conditions. On October 8, the FDA classified the action as a Class II recall, and it appeared in the agency's October 14 enforcement report, as detailed by Managed Healthcare Executive and Becker's Hospital Review.

The recalled product is Tirzepatide Injection 18 mg/mL in 4 mL multidose vials, distributed nationwide. The same enforcement report also lists one lot of the company's NAD+ Injection 200 mg/mL for the same reason. A Class II classification means the FDA believes use of the product may cause temporary or medically reversible health problems, and that the chance of serious harm is remote — a middle-tier concern, not a worst-case one.

Important context: "lack of assurance of sterility" does not mean contamination was found in these vials. It means the facility cannot prove the vials were made under conditions that guarantee sterility — which, for a medication you inject under your skin, is a standard that matters.

The recall covers a specific, identifiable set of vials. According to ConsumerAffairs, here is what to look for on your vial label:

• Product: Tirzepatide Injection, 18 mg/mL, in a 4 mL multidose vial
• NDC number: 85091-001-18
• Lot numbers: AP-202622 through AP-202644 (lot AP-202626 is not included)
• Beyond-use dates: October 7 through November 26, 2026

If your vial matches, stop using it and contact the pharmacy that dispensed it along with your prescriber for instructions and a replacement. Do not simply skip doses and wait: stopping tirzepatide abruptly can mean losing ground on your weight loss plan, and if you take it for blood sugar control, going without a plan is riskier than making one phone call.

If your tirzepatide came from a different pharmacy, or the label does not match the lots above, your medication is not part of this recall. Brand-name Zepbound and Mounjaro pens are not affected at all.

Tirzepatide is injected subcutaneously, which means anything in the vial — medication or contaminant — goes past the body's main defensive barrier, the skin. A non-sterile injectable can cause infections at the injection site or, less commonly, more serious systemic infections. That is why the FDA holds sterile compounding to detailed standards, and why it acts even when no contamination has actually been detected.

This recall did not come out of nowhere. After inspecting the facility in May 2025, the FDA issued a warning letter in December 2025 citing problems in its sterile production practices. The broader picture matters too: because compounded drugs are not FDA-approved, the agency does not review them for safety, effectiveness, or quality before they reach patients. The FDA had received about 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026 — numbers the agency considers likely underreported.

None of that means all compounded medication is dangerous. Legitimate, state-licensed US pharmacies fill compounded prescriptions safely every day. It means the pharmacy behind your vial matters as much as the molecule inside it.

Recalls like this one are a reason to ask questions, not to panic. If compounded tirzepatide is part of your treatment plan, you are entitled to know exactly where it comes from. Three questions worth asking any provider or telehealth service:

• Which pharmacy fills my prescription? You should get a specific name and state licensure, not a vague answer.
• Is it a licensed US pharmacy? This recall involved a US facility, but the riskiest products remain unlicensed online sellers and "research chemical" vendors, which operate with no oversight at all.
• Who do I contact if something seems off? A legitimate service has a care team that responds — and that proactively notifies you if a recall ever touches your medication.

This is the second supply chain story to hit compounded GLP-1s this month, after the FDA's import alert on overseas ingredient suppliers. The pattern is consistent: oversight is tightening, and the gap between accountable pharmacies and corner-cutters is getting more visible. That is good news for patients who use reputable sources.

Recall or no recall, tirzepatide has a known safety profile you should discuss with a licensed provider before starting. Common side effects include nausea, vomiting, diarrhea, constipation, and decreased appetite — most pronounced when starting or increasing doses, and often manageable with anti-nausea support. Tirzepatide is not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, and your provider should review your history of pancreatitis, gallbladder disease, and any diabetes medications before prescribing. Any injection that produces unusual redness, swelling, warmth at the site, or fever warrants a prompt call to your care team.

If this recall has you rethinking where your weight loss medication comes from, that instinct is a healthy one. At JoeyMed, every treatment plan starts with a review by a licensed provider, and prescriptions — including compounded tirzepatide (Tirz HD) — are filled through licensed US pharmacies, with a care team you can actually reach if you have questions about your medication, your lot, or your plan. If you currently have tirzepatide vials from any source, checking the label against the lots above takes under a minute. And if you are weighing whether a GLP-1 medication is right for you, a licensed provider can help you decide based on your health history — not a checkout page. Visit joeymed.com/weight-loss to take the first step.